Publicacións en colaboración con investigadores/as de Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (7)

2023

  1. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

    Journal of Thrombosis and Haemostasis

  2. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799

2022

  1. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114

2020

  1. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

    European Journal of Haematology, Vol. 104, Núm. 6, pp. 594-601

  2. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154

2016

  1. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

    Haemophilia, Vol. 22, Núm. 4, pp. e259-e266

2010

  1. ITER study of patients with haemo philia A and factor VIII inhibitors

    Hamostaseologie, Vol. 30, Núm. SUPPL.1, pp. 46-47